Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Shares of Tango Therapeutics Skyrocketed This Week


Shares of Tango Therapeutics (NASDAQ: TNGX) were up more than 91% for the week as of Thursday's close, according to data provided by S&P Global Market Intelligence. The clinical-stage biotech company's stock closed last week at $3.40 and reached a 52-week high of $9.39 on Wednesday.

The company, which focuses on precision oncology therapies, reported second-quarter earnings on Monday. Tango focused on the progress it is making with early-stage pipeline candidates. The company said it had begun dosing in two phase 1/2 trials, including TNG462 to treat MTAP-deleted tumors and TNG620 as a combination therapy with pembrolizumab to treat STK11-mutant solid tumors. Tango also is looking at TNG908 in a phase 1/2 trial to treat MTAP-deleted cancers and expects additional data from the trial next year.

According to Tango, 10% to 15% of all human cancers are associated with the deletion of the MTAP enzyme.

Continue reading


Source Fool.com

Like: 0
Share

Comments